Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Satsuma Pharmaceuticals, Inc. (STSA) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/12/2023 SC 13D/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Satsuma Pharmaceuticals, Inc.
06/09/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/09/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/09/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/08/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
06/08/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/08/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/08/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/08/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/08/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/08/2023 SC 13D/A Shin Nippon Biomedical Laboratories, Ltd. reports a 100% stake in SATSUMA PHARMACEUTICALS, INC.
06/08/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/08/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
06/08/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/08/2023 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Fifth Amended and Restated Certificate of Incorporation of the Company",
"Amended and Restated Bylaws of the Company"
06/08/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
06/08/2023 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
05/26/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
05/18/2023 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
05/18/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
05/18/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Satsuma Pharmaceuticals Announces FDA Acceptance of 505 NDA for STS101, a Novel and Investigational Dihydroergotamine Nasal Powder Product for the Acute Treatment of Migraine"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 SC 13E3 Form SC 13E3 - Going private transaction by certain issuers:
05/05/2023 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
05/05/2023 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
05/02/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
04/18/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
04/17/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
04/17/2023 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
04/17/2023 8-K Quarterly results
04/17/2023 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
03/28/2023 10-K Annual Report for the period ended December 31, 2022
03/28/2023 8-K Quarterly results
02/14/2023 SC 13G/A SAMLYN CAPITAL, LLC reports a 0% stake in Satsuma Pharmaceuticals, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy